| __timestamp | Viatris Inc. | Zoetis Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1499100000 | 1643000000 |
| Thursday, January 1, 2015 | 1923500000 | 1532000000 |
| Friday, January 1, 2016 | 2351400000 | 1364000000 |
| Sunday, January 1, 2017 | 2564000000 | 1334000000 |
| Monday, January 1, 2018 | 2397300000 | 1484000000 |
| Tuesday, January 1, 2019 | 2503400000 | 1638000000 |
| Wednesday, January 1, 2020 | 3344600000 | 1726000000 |
| Friday, January 1, 2021 | 4529200000 | 2001000000 |
| Saturday, January 1, 2022 | 4179100000 | 2009000000 |
| Sunday, January 1, 2023 | 4650100000 | 2151000000 |
| Monday, January 1, 2024 | 2318000000 |
Igniting the spark of knowledge
In the ever-evolving pharmaceutical industry, understanding the financial dynamics of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Viatris Inc. from 2014 to 2023. Over this period, Viatris Inc. has seen a significant increase in its SG&A expenses, growing by approximately 210%, from $1.5 billion in 2014 to $4.65 billion in 2023. In contrast, Zoetis Inc. has maintained a more stable trajectory, with a 31% increase, from $1.64 billion to $2.15 billion. This disparity highlights Viatris's aggressive expansion and operational strategies compared to Zoetis's steady growth. As the pharmaceutical landscape continues to shift, these financial insights provide a window into the strategic priorities of these industry giants.
Cost Management Insights: SG&A Expenses for AstraZeneca PLC and Zoetis Inc.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Zoetis Inc. vs Dr. Reddy's Laboratories Limited: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Zoetis Inc. or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Zoetis Inc. and Agios Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
Alnylam Pharmaceuticals, Inc. and Viatris Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and BioMarin Pharmaceutical Inc.
Selling, General, and Administrative Costs: Viatris Inc. vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.